Michal Kirshenbaum1,2, Raoul Orvieto3,4,5. 1. Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel. raoul.orvieto@sheba.health.gov.il. 4. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. raoul.orvieto@sheba.health.gov.il. 5. The Tarnesby-Tarnowski Chair for Family Planning and Fertility Regulation, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. raoul.orvieto@sheba.health.gov.il.
Abstract
PURPOSE: Primary ovarian insufficiency (POI) represents ovarian dysfunction related to very early aging of the ovaries. While the cause of POI in a majority of clinical cases remains undefined, autoimmunity is responsible for approximately 4-30% of POI cases. In the present paper, we aim to provide a critical appraisal and update review on the role of autoimmunity in POI patients. METHODS: A literature review was conducted for all relevant articles reporting on POI and autoimmunity. PubMed/MEDLINE and the Cochrane library were searched for the best available evidence on this topic. RESULTS: Patients with POI and coexisting autoimmunity are indistinguishable from those with negative autoimmune screen with regard to age of onset, prevalence of primary amenorrhea, or their endocrine profiles. A specific noninvasive reliable diagnostic test for the diagnosis of an autoimmune etiology is lacking; therefore, patients should be screened for the most common autoantibodies, i.e., steroid cell antibodies, anti-ovarian antibodies, and anti-thyroid antibodies. Moreover, treatment strategies to POI infertility are lacking and controversial. CONCLUSIONS: Nowadays, guidelines for the treatment of autoimmune POI are not available. Moreover, since diagnostic and treatment strategies to POI infertility are still lacking and controversial, further large clinical studies are needed to investigate the true impact of autoimmunity on POI and to identify the selected groups of patients who are most likely to benefit from immunossuprresive treatment.
PURPOSE:Primary ovarian insufficiency (POI) represents ovarian dysfunction related to very early aging of the ovaries. While the cause of POI in a majority of clinical cases remains undefined, autoimmunity is responsible for approximately 4-30% of POI cases. In the present paper, we aim to provide a critical appraisal and update review on the role of autoimmunity in POI patients. METHODS: A literature review was conducted for all relevant articles reporting on POI and autoimmunity. PubMed/MEDLINE and the Cochrane library were searched for the best available evidence on this topic. RESULTS:Patients with POI and coexisting autoimmunity are indistinguishable from those with negative autoimmune screen with regard to age of onset, prevalence of primary amenorrhea, or their endocrine profiles. A specific noninvasive reliable diagnostic test for the diagnosis of an autoimmune etiology is lacking; therefore, patients should be screened for the most common autoantibodies, i.e., steroid cell antibodies, anti-ovarian antibodies, and anti-thyroid antibodies. Moreover, treatment strategies to POI infertility are lacking and controversial. CONCLUSIONS: Nowadays, guidelines for the treatment of autoimmune POI are not available. Moreover, since diagnostic and treatment strategies to POI infertility are still lacking and controversial, further large clinical studies are needed to investigate the true impact of autoimmunity on POI and to identify the selected groups of patients who are most likely to benefit from immunossuprresive treatment.
Authors: Carlo Alviggi; Sandro C Esteves; Raoul Orvieto; Alessandro Conforti; Antonio La Marca; Robert Fischer; Claus Y Andersen; Klaus Bühler; Sesh K Sunkara; Nikolaos P Polyzos; Ida Strina; Luigi Carbone; Fabiola C Bento; Daniela Galliano; Hakan Yarali; Lan N Vuong; Michael Grynberg; Panagiotis Drakopoulos; Pedro Xavier; Joaquin Llacer; Fernando Neuspiller; Marcos Horton; Matheus Roque; Evangelos Papanikolaou; Manish Banker; Michael H Dahan; Shu Foong; Herman Tournaye; Christophe Blockeel; Alberto Vaiarelli; Peter Humaidan; Filippo M Ubaldi Journal: Reprod Biol Endocrinol Date: 2020-05-13 Impact factor: 5.211
Authors: Yan Zhao; Jiao Ma; Peiye Yi; Jun Wu; Feiyan Zhao; Wan Tu; Wenjing Liu; Tianda Li; Yan Deng; Jie Hao; Hongmei Wang; Long Yan Journal: Stem Cell Res Ther Date: 2020-11-04 Impact factor: 6.832
Authors: Anna Szeliga; Anna Calik-Ksepka; Marzena Maciejewska-Jeske; Monika Grymowicz; Katarzyna Smolarczyk; Anna Kostrzak; Roman Smolarczyk; Ewa Rudnicka; Blazej Meczekalski Journal: Int J Mol Sci Date: 2021-03-05 Impact factor: 5.923